NEW YORK: Novartis AG said Tuesday it will take a charge of US$590 million during the third quarter as it discontinues development of a potential hepatitis C drug and an antifungal product.
The Swiss company and its partner Human Genome Sciences Inc. had expressed concerns earlier in the year that the potential hepatitis C treatment Joulferon, known as Zalbin in the U.S., would not pass regulatory authority reviews.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!